Skip to content

A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of the Novavax logo displayed in this illustration taken on October 30, 2020.

Dado Ruvic | Reuters

The Novavax coronavirus vaccine could be cleared by regulators for use in several countries, including the United States, in the coming months, the CEO of the vaccine maker said on Monday.

The company has filed for emergency approval with 10 different regulatory agencies, Stanley Erck told CNBC’s “Squawk on the Street.” It is currently available for use in 170 countries, he said.

“I think in the next 90 days we could have them every 10,” Erck said.

The company submitted its final data to the United States Food and Drug Administration on New Years Eve. It is still preparing to file the full emergency use authorization application, but it will do so shortly and s ‘expects a decision from US regulators in February, he said.

Erck did not name the other regulatory bodies to which he submitted requests. According to the company’s website, it recently applied for approval in Japan, the United Arab Emirates, Singapore, New Zealand, Canada, Australia, South Africa and the United Kingdom.

Several other health agencies around the world have already approved the vaccine.

Novavax recently shipped its first doses of the vaccine to Europe, Erck said. It was cleared by European Union regulators last month.

“Everything is falling into place,” Erck told CNBC.

The vaccine could be in high demand. Novavax’s vaccine is protein-based and uses an alternative technology to more popular mRNA vaccines. This could help convince those skeptical of the new mRNA technology to get vaccinated against the virus, Erck said. It also appears to have a significantly lower rate of unwanted side effects, compared to other vaccines.

cnbc Business

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.